Literature DB >> 10964160

Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.

L Duvillard1, F Pont, E Florentin, C Galland-Jos, P Gambert, B Vergès.   

Abstract

BACKGROUND: Kinetic abnormalities of apolipoprotein B (apoB)-containing lipoproteins in noninsulin-dependent diabetes mellitus (NIDDM) remain poorly understood. To get further insight into these abnormalities we performed a stable isotope kinetic experiment comparing the metabolism of apoB-containing lipoproteins in moderately severe NIDDM patients and healthy control subjects.
METHODS: The study was performed in the fed state. Subjects underwent a primed infusion of 0.7 mg kg(-1) of L-[1-(13)C]leucine followed by a 16-h constant infusion of 0.7 mg kg(-1) h(-1). [13C]Leucine enrichment in apoB was measured by gas chromatography/combustion/isotope ratio mass spectrometry.
RESULTS: In NIDDM patients, we observed a 3.49- and 4.52-fold increase of very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL) apoB plasma concentrations, respectively (P<0.01). VLDL apoB production was increased by 41% (P<0.05) and fractional catabolic rate towards IDL and low-density lipoprotein (LDL) was decreased by 61% (P<0.05). The increased IDL apoB plasma concentration was also related to a major catabolic defect (-78%; P<0.01). For most patients, plasma LDL apoB concentration was comparable to that of controls. Nevertheless, LDL apoB metabolism was impaired in NIDDM subjects, with both a decreased LDL catabolic rate (-28%; P<0.05) and a trend towards a diminished synthesis.
CONCLUSION: NIDDM is associated with multiple apoB metabolism abnormalities that are potentially atherogenic. In addition to the increased number of circulating VLDL and IDL particles, the increased residence time observed on all apoB-containing lipoproteins may promote the development of atherosclerotic lesions, by potentiating their oxidizability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964160

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  25 in total

1.  Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia.

Authors:  Heiner K Berthold; Jessica Mertens; Julia Birnbaum; Susanne Brämswig; Thomas Sudhop; P Hugh R Barrett; Klaus von Bergmann; Ioanna Gouni-Berthold
Journal:  Lipids       Date:  2010-05-12       Impact factor: 1.880

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

Authors:  Christophe Marçais; Bruno Verges; Sybil Charrière; Valérie Pruneta; Micheline Merlin; Stéphane Billon; Laurence Perrot; Jocelyne Drai; Agnès Sassolas; Len A Pennacchio; Jamila Fruchart-Najib; Jean-Charles Fruchart; Vincent Durlach; Philippe Moulin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

4.  Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Authors:  Amirfarbod Yazdanyar; Xian-Cheng Jiang
Journal:  Hepatology       Date:  2012-06-11       Impact factor: 17.425

Review 5.  Role of lipotoxicity in endothelial dysfunction.

Authors:  Jeong-a Kim; Monica Montagnani; Sruti Chandrasekran; Michael J Quon
Journal:  Heart Fail Clin       Date:  2012-08-10       Impact factor: 3.179

6.  Changes in glucose metabolism and mRNA expression of IRS-2 in rats exposed to phoxim and the protective effects of vitamin E.

Authors:  Jing Zhang; Wentao Song; Yuecheng Sun; Baojing Cheng; Anshan Shan
Journal:  Toxicol Res (Camb)       Date:  2017-12-01       Impact factor: 3.524

7.  SHP-2 and PI3-kinase genes PTPN11 and PIK3R1 may influence serum apoB and LDL cholesterol levels in normal women.

Authors:  Y Jamshidi; S B Gooljar; H Snieder; X Wang; D Ge; R Swaminathan; T D Spector; S D O'Dell
Journal:  Atherosclerosis       Date:  2007-01-09       Impact factor: 5.162

Review 8.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

9.  Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.

Authors:  B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

Review 10.  Nutritional systems biology modeling: from molecular mechanisms to physiology.

Authors:  Albert A de Graaf; Andreas P Freidig; Baukje De Roos; Neema Jamshidi; Matthias Heinemann; Johan A C Rullmann; Kevin D Hall; Martin Adiels; Ben van Ommen
Journal:  PLoS Comput Biol       Date:  2009-11-26       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.